650
SERUM HEPATITIS B CORE-RELATED ANTIGEN (HBCRAG)
LEVEL PREDICTS HEPATOCELLULAR CARCINOMA IN
PATIENTS WITH CHRONIC HEPATITIS B
Grace L Wong1, Lilian Yan Liang2, Hidenori Toyoda3, Henry Lik
Yuen Chan4, Yee-Kit Tse1, Terry Cheuk-Fung Yip5, Becky W.Y.
Yuen6, Toshifumi Tada3, Takashi Kumada7 and Vincent Wai-
Sun Wong4, (1)Institute of Digestive Disease, Department of
Medicine and Therapeutics, The Chinese University of Hong
Kong, (2)Department of Medicine and Therapeutics, Institute
of Digestive Disease, The Chinese University of Hong Kong,
(3)Department of Gastroenterology, Ogaki Municipal Hospital,
(4)Institute of Digestive Disease, Department of Medicine
and Therapeutics, and State Key Laboratory of Digestive
Disease, The Chinese University of Hong Kong, Hong Kong,
(5)Department of Medicine and Therapeutics, Institute of
Digestive Disease, The Chinese University of Hong Kong,
Hong Kong, (6)Department of Statistics, The Chinese
University of Hong Kong, (7)Department of Nursing, Gifu
Kyoritsu University
Background: Previous studies suggested that high
serum HBcrAg level is associated with the development of
hepatocellular carcinoma (HCC) in untreated CHB patients
We aimed to evaluate the role of serum HBcrAg levels to
predict HCC in nucleos(t)ide analogues (NA) treated patients
Methods: NA-treated CHB patients with pre-treatment serum
samples available were recruited Pre-treatment serum HBsAg
and HBcrAg and levels were measured Primary endpoint was
HCC Results: 1,424 CHB patients (mean age 54 ± 12 years,
72% male, 81% entecavir-treated and 27% tenofovir-treated,
25% HBeAg positive) were included The mean baseline
serum HBV DNA, HBsAg and HBcrAg levels were 3.99 ± 2.30
log10 IU/mL, 2 9 ± 0 9 log10 IU/mL, and 4 2 ± 1 3 log10 U/mL,
respectively 88 patients developed HCC during a follow-up of
45 ± 20 months Serum HBcrAg level above 2 9 log10 IU/mL
was an independent risk factor of HCC (adjust hazard ratio
2 83, 95% CI 1 39-5 78, p=0 004), in addition to male gender,
advanced age, low platelet count and low serum albumin
level. In contrast, HBeAg and HBV DNA at baseline were not
associated with HCC HBcrAg level remained an independent
risk factor in the subgroup of patients with negative HBeAg, or
low serum HBV DNA < 2,000 IU/mL at baseline. Conclusion:
High baseline serum HBcrAg level predicts higher risk of HCC
in NA-treated patients. 作者: StephenW 时间: 2019-10-31 17:28